Sugi Predict

Sugi Predict / Compounds / SCHEMBL299382

SCHEMBL299382

SCHEMBL299382

Nc1cccc(C(=O)c2c[nH]c3ncc(Br)cc23)c1F

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRAF P15056 3/20 0.51
▸ CYP2C9 P11712 4/20 0.46
▸ CYP3A4 P08684 2/20 0.44
▸ ROCK2 O75116 2/20 0.42
▸ PRKD3 O94806 2/20 0.42
▸ MAP4K4 O95819 2/20 0.42
▸ CDK1 P06493 2/20 0.42
▸ MARK3 P27448 2/20 0.42
▸ FLT4 P35916 2/20 0.42
▸ FLT3 P36888 2/20 0.42
▸ FRK P42685 2/20 0.42
▸ CLK2 P49760 2/20 0.42
▸ NEK4 P51957 2/20 0.42
▸ CDK5 Q00535 2/20 0.42
▸ MAP4K2 Q12851 2/20 0.42
▸ STK3 Q13188 2/20 0.42
▸ CAMK2B Q13554 2/20 0.42
▸ CAMK2G Q13555 2/20 0.42
▸ CAMK2D Q13557 2/20 0.42
▸ DYRK1A Q13627 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3506159 0.88 BRAF (0.51) BRAFCYP2C9CYP3A4ROCK2PRKD3
SCHEMBL2351343 0.88 CYP2C9 (0.48) BRAFCYP2C9CYP3A4ROCK2PRKD3
SCHEMBL25173228 0.88 BRAF (0.45) BRAFCYP2C9CYP3A4ROCK2PRKD3
SCHEMBL30376683 0.88 BRAF (0.45) BRAFCYP2C9CYP3A4ROCK2PRKD3
SCHEMBL856153 0.87 BRAF (0.52) BRAFCYP2C9CYP3A4ROCK2PRKD3
SCHEMBL2357075 0.86 BRAF (0.49) BRAFCYP2C9CYP3A4MAP4K4FLT3
SCHEMBL856098 0.86 BRAF (0.51) BRAFCYP2C9CYP3A4ROCK2PRKD3
SCHEMBL3705469 0.86 CYP3A4 (0.52) BRAFCYP2C9CYP3A4MAP4K4FLT3
SCHEMBL2883747 0.86 CYP2C9 (0.46) BRAFCYP2C9CYP3A4ROCK2PRKD3
SCHEMBL855368 0.86 BRAF (0.51) BRAFCYP2C9CYP3A4ROCK2PRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260115296-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES UNIV YALE (US) 2026-04-30 — — US disclosed
US-11986531-B2 Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides ARVINAS OPERATIONS, INC. (US) 2024-05-21 — — US disclosed
US-20230277534-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2023-09-07 — — US disclosed
US-20230000994-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES YALE UNIVERSITY 2023-01-05 — — US disclosed
US-20230000994-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES YALE UNIVERSITY 2023-01-05 — — US disclosed
US-11337976-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2022-05-24 — — US disclosed
US-11173211-B2 Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides ARVINAS OPERATIONS, INC. (US) 2021-11-16 — — US disclosed
US-11173211-B2 Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides ARVINAS OPERATIONS, INC. (US) 2021-11-16 — — US disclosed
CN-113164775-A Polycyclic compounds and methods for rapid accelerated targeted degradation of fibrosarcoma polypeptides 阿尔维纳斯运营股份有限公司 2021-07-23 — — CN disclosed
EP-3846907-A1 POLYCYCLIC COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES Arvinas Operations, Inc. (US) 2021-07-14 — — EP disclosed
US-20100286142-A1 Compounds and Methods for Kinase Modulation, and Indications Therefor PLEXXIKON, INC. 2010-11-11 — — US disclosed
US-20100286142-A1 Compounds and Methods for Kinase Modulation, and Indications Therefor PLEXXIKON, INC. 2010-11-11 — — US disclosed
WO-2010129570-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. (US) 2010-11-11 — — WO disclosed
WO-2010129570-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. (US) 2010-11-11 — — WO disclosed
WO-2010129567-A1 PYRROLO [2, 3. B] PYRIDINES WHICH INHIBIT RAF PROTEIN KINASE PLEXXIKON, INC. (US) 2010-11-11 — — WO disclosed
WO-2010129567-A1 PYRROLO [2, 3. B] PYRIDINES WHICH INHIBIT RAF PROTEIN KINASE PLEXXIKON, INC. (US) 2010-11-11 — — WO disclosed
US-20100286142-A1 Compounds and Methods for Kinase Modulation, and Indications Therefor PLEXXIKON, INC. 2010-11-11 — — US disclosed
US-20100256365-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. 2010-10-07 — — US disclosed
US-20100249118-A1 protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents PLEXXIKON INC. 2010-09-30 — — US disclosed
WO-2007002325-A1 PYRROLO[2,3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS PLEXXIKON, INC. (US) 2007-01-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249118-A1 protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents MAP4K1, MAP4K2, MAP3K1 BRAF 95/4885CYP2C9 4869/4885CYP3A4 4851/4885
US-11173211-B2 Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides CRBN, ARAF, VHL BRAF 4/4885CYP2C9 4808/4885CYP3A4 4716/4885
US-11337976-B2 Compounds and methods for kinase modulation, and indications therefor MAP3K20, PRKACA, MAP3K13 BRAF 49/4885CYP2C9 4771/4885CYP3A4 4679/4885
US-20230277534-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, PRKACA, MAP3K13 BRAF 49/4885CYP2C9 4771/4885CYP3A4 4679/4885
US-20230000994-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES CRBN, ARAF, VHL BRAF 4/4885CYP2C9 4808/4885CYP3A4 4716/4885
US-20100286142-A1 Compounds and Methods for Kinase Modulation, and Indications Therefor BRAF, ARAF, RAF1 BRAF 1/4885CYP2C9 2237/4885CYP3A4 2892/4885
US-20100256365-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, MAP3K13, MAP3K8 BRAF 48/4885CYP2C9 4746/4885CYP3A4 4658/4885
US-11986531-B2 Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides CRBN, ARAF, VHL BRAF 4/4885CYP2C9 4808/4885CYP3A4 4716/4885
US-20260115296-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES CRBN, VHL, ADRM1 BRAF 8/4885CYP2C9 4810/4885CYP3A4 4768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.